BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36240445)

  • 21. Has MRD monitoring superseded other prognostic factors in adult ALL?
    Brüggemann M; Raff T; Kneba M
    Blood; 2012 Nov; 120(23):4470-81. PubMed ID: 23033265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-throughput sequencing of peripheral blood for minimal residual disease monitoring in childhood precursor B-cell acute lymphoblastic leukemia: A prospective feasibility study.
    Bartram J; Wright G; Adams S; Archer P; Brooks T; Edwards D; Hancock J; Knecht H; Inglott S; Mountjoy E; Roynane M; Wakeman S; Moppett J; Hubank M; Goulden N
    Pediatr Blood Cancer; 2022 Mar; 69(3):e29513. PubMed ID: 34971078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.
    Conter V; Bartram CR; Valsecchi MG; Schrauder A; Panzer-Grümayer R; Möricke A; Aricò M; Zimmermann M; Mann G; De Rossi G; Stanulla M; Locatelli F; Basso G; Niggli F; Barisone E; Henze G; Ludwig WD; Haas OA; Cazzaniga G; Koehler R; Silvestri D; Bradtke J; Parasole R; Beier R; van Dongen JJ; Biondi A; Schrappe M
    Blood; 2010 Apr; 115(16):3206-14. PubMed ID: 20154213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
    Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
    Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next-generation sequencing of PTEN mutations for monitoring minimal residual disease in T-cell acute lymphoblastic leukemia.
    Germano G; Valsecchi MG; Buldini B; Cazzaniga G; Zanon C; Silvestri D; Te Kronnie G; Basso G; Paganin M
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28025. PubMed ID: 31571345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all.
    Kuiper RP; Hoogeveen PG; Bladergroen R; van Dijk F; Sonneveld E; van Leeuwen FN; Boer J; Sergeeva I; Feitsma H; den Boer ML; van der Velden VHJ
    Br J Haematol; 2021 Sep; 194(5):888-892. PubMed ID: 34337744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update.
    Reyes-Barron C; Burack WR; Rothberg PG; Ding Y
    Crit Rev Oncog; 2017; 22(5-6):559-567. PubMed ID: 29604931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
    Kim R; Bergugnat H; Pastoret C; Pasquier F; Raffoux E; Larcher L; Passet M; Grardel N; Delabesse E; Kubetzko S; Caye-Eude A; Meyer C; Marschalek R; Lafage-Pochitaloff M; Thiebaut-Bertrand A; Balsat M; Escoffre-Barbe M; Blum S; Baumann M; Banos A; Straetmans N; Gallego-Hernanz MP; Chalandon Y; Graux C; Soulier J; Leguay T; Hunault M; Huguet F; Lhéritier V; Dombret H; Boissel N; Clappier E
    Blood; 2023 Nov; 142(21):1806-1817. PubMed ID: 37595275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
    van der Velden VH; Cazzaniga G; Schrauder A; Hancock J; Bader P; Panzer-Grumayer ER; Flohr T; Sutton R; Cave H; Madsen HO; Cayuela JM; Trka J; Eckert C; Foroni L; Zur Stadt U; Beldjord K; Raff T; van der Schoot CE; van Dongen JJ;
    Leukemia; 2007 Apr; 21(4):604-11. PubMed ID: 17287850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
    Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
    Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection.
    Theunissen PMJ; de Bie M; van Zessen D; de Haas V; Stubbs AP; van der Velden VHJ
    Leuk Res; 2019 Jan; 76():98-104. PubMed ID: 30389174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS.
    Knecht H; Reigl T; Kotrová M; Appelt F; Stewart P; Bystry V; Krejci A; Grioni A; Pal K; Stranska K; Plevova K; Rijntjes J; Songia S; Svatoň M; Froňková E; Bartram J; Scheijen B; Herrmann D; García-Sanz R; Hancock J; Moppett J; van Dongen JJM; Cazzaniga G; Davi F; Groenen PJTA; Hummel M; Macintyre EA; Stamatopoulos K; Trka J; Langerak AW; Gonzalez D; Pott C; Brüggemann M; Darzentas N;
    Leukemia; 2019 Sep; 33(9):2254-2265. PubMed ID: 31227779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.
    Willemse MJ; Seriu T; Hettinger K; d'Aniello E; Hop WC; Panzer-Grümayer ER; Biondi A; Schrappe M; Kamps WA; Masera G; Gadner H; Riehm H; Bartram CR; van Dongen JJ
    Blood; 2002 Jun; 99(12):4386-93. PubMed ID: 12036866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in childhood acute lymphoblastic leukemia using a low-cost PCR strategy.
    Assumpção JG; Ganazza MA; de Araújo M; Silva AS; Scrideli CA; Brandalise SR; Yunes JA
    Pediatr Blood Cancer; 2010 Dec; 55(7):1278-86. PubMed ID: 20730889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry.
    Alm SJ; Engvall C; Asp J; Palmqvist L; Abrahamsson J; Fogelstrand L
    Int J Lab Hematol; 2017 Apr; 39(2):121-128. PubMed ID: 28004528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
    Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
    Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Two Quantitative PCR-Based Assays for Detection of Minimal Residual Disease in B-Precursor Acute Lymphoblastic Leukemia Harboring Three Major Fusion Transcripts.
    Huang YJ; Kuo MC; Jaing TH; Liu HC; Yeh TC; Chen SH; Lin TL; Yang CP; Wang PN; Sheen JM; Chang TK; Chang CH; Hu SF; Huang TY; Wang SC; Wu KH; Chiou SS; Hsiao CC; Shih LY
    J Mol Diagn; 2021 Oct; 23(10):1373-1379. PubMed ID: 34325057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.
    Shirai R; Osumi T; Keino D; Nakabayashi K; Uchiyama T; Sekiguchi M; Hiwatari M; Yoshida M; Yoshida K; Yamada Y; Tomizawa D; Takae S; Kiyokawa N; Matsumoto K; Yoshioka T; Hata K; Hori T; Suzuki N; Kato M
    Int J Hematol; 2023 Jun; 117(6):910-918. PubMed ID: 36867356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.
    Kruse A; Abdel-Azim N; Kim HN; Ruan Y; Phan V; Ogana H; Wang W; Lee R; Gang EJ; Khazal S; Kim YM
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.